Designed to stabilize and fuse the SI joint
SI-BONE, Inc. has developed a minimally invasive surgical (MIS), innovative, patented, sacroiliac implant system for sacroiliac (SI) joint conditions including disruptions and degenerative sacroiliitis. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit. For information about the risks, visit: www.si-bone.com/risks
The iFuse Implant System® consists of titanium implants and associated surgical instruments. Typically, patients receive three triangular-shaped titanium implants. Available implant lengths range from 30mm to 70mm in 5mm increments. These implants are delivered to the sacroiliac (SI) joint using a cannulated delivery system designed to protect soft tissue. The surgery is performed through a 2-3cm incision.
Potential iFuse benefits
With the iFuse Implant System, there is no need for:
Possible benefits versus traditional surgical SI joint fixation
Possible benefits of a minimally invasive surgical procedure
* MacBarb, et al., “Fortifying the Bone-Implant Interface Part II: An In Vivo Evaluation of 3D-Printed and TPS-Coated Triangular Implants,” Int J Spine Surg, 2017; 11.
The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit. For information about the risks, visit: www.si-bone.com/risks